Table 2.
Demographic information on all cohorts of patients with UC
| STARR |
Optum |
|||
|---|---|---|---|---|
| Comparator | Atorvastatin | Comparator | Atorvastatin | |
| (n = 596) | (n = 231) | (n = 4940) | (n = 2881) | |
| Age (mean (SD)) | 56.68 (16.15) | 62.51 (12.61) | 55.45 (16.04) | 59.28 (12.76) |
| Sex | ||||
| Female | 299 (50.2) | 101 (43.7) | 2593 (52.5) | 1288 (44.7) |
| Male | 297 (49.8) | 130 (56.3) | 2346 (47.5) | 1591 (55.2) |
| Unknown | 0 (0.0) | 0 (0.0) | 1 (0.0) | 2 (0.1) |
| Comparator Drug Rx | ||||
| Niacin (%) | 21 (3.5) | 12 (5.2) | 201 (4.1) | 81 (2.8) |
| Ezetimibe (%) | 9 (1.5) | 8 (3.5) | 436 (8.8) | 177 (6.1) |
| Cholestyramine (%) | 27 (4.5) | 5 (2.2) | 866 (17.5) | 132 (4.6) |
| Omega FA (%) | 44 (7.4) | 22 (9.5) | 241 (4.9) | 71 (2.5) |
| Benazepril (%) | 16 (2.7) | 12 (5.2) | 301 (6.1) | 90 (3.1) |
| Furosemide (%) | 181 (30.4) | 50 (21.6) | 1597 (32.3) | 483 (16.8) |
| Losartan (%) | 75 (12.6) | 38 (16.5) | 1055 (21.4) | 385 (13.4) |
| Propranolol (%) | 46 (7.7) | 5 (2.2) | 449 (9.1) | 65 (2.3) |
| Metformin (%) | 92 (15.4) | 40 (17.3) | 1186 (24.0) | 505 (17.5) |
| Hydralazine (%) | 119 (20.0) | 33 (14.3) | 150 (3.0) | 72 (2.5) |
| Comorbidities | ||||
| CAD (%) | 88 (14.8) | 71 (30.7) | 2023 (41.0) | 1366 (47.4) |
| Cerebrovascular (%) | 35 (5.9) | 38 (16.5) | 1695 (34.3) | 1236 (42.9) |
| PVD (%) | 53 (8.9) | 23 (10.0) | 952 (19.3) | 680 (23.6) |
| CHF (%) | 70 (11.7) | 36 (15.6) | 777 (15.7) | 431 (15.0) |
| Colectomy (%) | 68 (11.4) | 10 (4.3) | 141 (2.9) | 42 (1.5) |
| Atorvastatin dose | 29.64 (20.42) | 27.11 (19.15) | ||
| (mean mg (SD)) | ||||
| IBD Rx | ||||
| Mesalamine (%) | 220 (36.9) | 85 (36.8) | 3303 (66.9) | 1844 (64.0) |
| Olsalazine (%) | 2 (0.3) | 1 (0.4) | 34 (0.7) | 15 (0.5) |
| Balsalazide (%) | 33 (5.5) | 15 (6.5) | 737 (14.9) | 395 (13.7) |
| Sulfasalazine (%) | 84 (14.1) | 40 (17.3) | 779 (15.8) | 543 (18.8) |
| Mercaptopurine (%) | 47 (7.9) | 26 (11.3) | 493 (10.0) | 254 (8.8) |
| Azathioprine (%) | 28 (4.7) | 12 (5.2) | 832 (16.8) | 357 (12.4) |
| Infliximab (%) | 28 (4.7) | 11 (4.8) | 395 (8.0) | 173 (6.0) |
| Adalimumab (%) | 8 (1.3) | 5 (2.2) | 254 (5.1) | 119 (4.1) |
| Certolizumab (%) | 0 (0.0) | 0 (0.0) | 26 (0.5) | 18 (0.6) |
| Natalizumab (%) | 0 (0.0) | 0 (0.0) | 2 (0.0) | 1 (0.0) |
| Budesonide (%) | 49 (8.2) | 21 (9.1) | 909 (18.4) | 425 (14.8) |
| Prednisone (%) | 245 (41.1) | 92 (39.8) | 3047 (61.7) | 1608 (55.8) |
| Prednisolone (%) | 147 (24.7) | 55 (23.8) | 1631 (33.0) | 1017 (35.3) |
| Vedolizumab (%) | 7 (1.2) | 2 (0.9) | 63 (1.3) | 19 (0.7) |
| Inflammatory Markers | ||||
| Albumin (mean g/dL (SD)) | 3.55 (0.76) | 3.70 (0.67) | 4.55 (7.54) | 4.98 (12.72) |
| CRP (mean mg/L (SD)) | 5.46 (9.08) | 4.55 (5.84) | 7.43 (6.03) | 8.12 (6.74) |
Abbreviations: CV, cardiovascular; CHF, chronic heart failure; CAD, coronary artery disease; PVD, peripheral vascular disease.